Latest On Orchard Therapeutics plc (ORTX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-19 19:49 EST | News | Orchard Therapeutics updates gene therapy data in metabolic disorders | N/A |  |
| 2023-05-15 19:19 EST | News | Orchard Therapeutics GAAP EPS of -$0.12, revenue of $1.23M | N/A | |
| 2023-04-25 01:40 EST | News | Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates | N/A | |
| 2023-03-28 16:56 EST | News | Orchard Therapeutics (ORTX) Investor Presentation - Slideshow' | N/A | |
| 2023-03-10 18:33 EST | News | Orchard Therapeutics plc (ORTX) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-06 09:18 EST | News | Orchard Therapeutics announces up to $188M strategic financing | N/A | |
| 2023-03-06 09:18 EST | News | Orchard Therapeutics GAAP EPS of -$0.06 beats by $0.15, revenue of $6.97M beats by $1.66M | N/A | |
| 2023-02-10 22:44 EST | News | Orchard Therapeutics announces 1-for-10 ADS ratio change | N/A | |
| 2023-01-05 18:29 EST | News | Orchard adds ~32% as FDA clears trial for metabolic disorder drug | N/A | |
| 2022-12-20 23:44 EST | News | Orchard Therapeutics: Growing A Position In This Undervalued Gene Therapy Play | N/A | |
| 2022-12-01 23:31 EST | News | Orchard's Libmeldy for rare disorder gets Swissmedic review | N/A | |
| 2022-11-14 20:39 EST | News | Orchard Therapeutics GAAP EPS of -$0.37 misses by $0.13, revenue of $5.78M beats by $1.37M | N/A | |
| 2022-11-14 20:39 EST | News | Orchard Therapeutics plc 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-11-14 20:39 EST | News | Orchard Therapeutics plc (ORTX) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-11 23:09 EST | News | Orchard Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2022-08-21 03:35 EST | News | Orchard Therapeutics: Gene Therapy For Rare Child Disease | N/A | |
| 2022-08-16 02:39 EST | News | Temasek boosts Amazon stake, exits Starbucks and Salesforce | N/A | |
| 2022-08-04 21:54 EST | News | Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M | N/A | |
| 2022-06-12 08:33 EST | News | With bluebird bio's success, what are other gene therapies companies to pay attention to? | N/A | |
| 2022-05-13 05:36 EST | News | Orchard Therapeutics PLC (ORTX) CEO Bobby Gaspar on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-12 10:21 EST | News | Orchard Therapeutics GAAP EPS of -$0.35 misses by $0.10, revenue of $5.52M beats by $1.48M | N/A | |
| 2022-05-11 16:53 EST | News | Orchard Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-03-30 12:37 EST | News | Orchard to cut ~30% workforce amid plans to refine portfolio; reports Q4 results | N/A | |
| 2022-03-30 12:37 EST | News | Orchard Therapeutics' (ORTX) CEO Bobby Gaspar on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-04 15:08 EST | News | Orchard wins reimbursement for stem cell gene therapy in U.K. | N/A | |
| 2022-01-21 21:34 EST | News | Orchard reports long term benefit of gene therapy Libmeldy for rare disorder | N/A | |
| 2022-01-20 14:16 EST | News | Orchard Therapeutics: Shadow Of Former Glory | N/A | |
| 2021-12-29 13:56 EST | News | Orchard Therapeutics assumed Overweight at Cantor with $9 target | N/A | |
| 2021-11-10 00:07 EST | News | Warning: ORTX is at high risk of performing badly | N/A | |
| 2021-11-04 22:48 EST | News | Orchard Therapeutics EPS misses by $0.04, misses on revenue | N/A | |
| 2021-09-27 10:05 EST | News | Orchard Therapeutics (ORTX) Investor Prentation - Slideshow | N/A | |
| 2021-09-22 17:30 EST | News | Oxford Biomedica plc reports 1H results | N/A | |
| 2021-08-16 11:30 EST | News | Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles | N/A | |
| 2021-08-04 21:27 EST | News | Orchard Therapeutics EPS beats by $0.04 | N/A | |
| 2021-07-22 15:59 EST | News | Orchard Therapeutics updates on gene therapy programs | N/A | |
| 2021-07-22 15:58 EST | News | Orchard Therapeutics draws a lower price target at Cantor on delayed milestones | N/A | |
| 2021-07-22 15:58 EST | News | Orchard Therapeutics inks strategic deal to develop HSC gene therapy for hereditary angioedema | N/A | |
| 2021-03-25 07:11 EST | News | Orchard Therapeutics: Curative Medicines For Immune-Related Diseases | N/A | |
| 2021-03-11 20:48 EST | News | Orchard Therapeutics: Slow And Steady, But Lacking Major Near-Term Catalysts | N/A | |
| 2021-03-11 00:49 EST | News | Bluebird bio upgraded to buy at Mizuho on safety update | N/A | |
| 2021-03-05 02:28 EST | Analyst Rating | The Analyst Target Price has increased from $14.89 to $15.11. | Buy | |
| 2021-03-04 17:45 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-03 20:02 EST | News | Orchard expands Be The Match Bio collaboration ahead of Libmeldy launch | N/A | |
| 2021-03-03 10:03 EST | Earnings Estimate | An EPS average of -$1.14 is estimated for the 2022 year. | Sell | |
| 2021-03-03 10:03 EST | Earnings Estimate | An EPS average of -$0.36 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-03-03 10:03 EST | Analyst Rating | The Analyst Target Price has decreased from $15.11 to $14.89. | Neutral | |
| 2021-02-18 13:38 EST | Analyst Rating | The Analyst Target Price has increased from $14.67 to $15.11. | Buy | |
| 2021-02-16 21:39 EST | News | Bluebird bio trial suspension hurts Orchard and AVROBIO | N/A | |
| 2021-02-11 22:20 EST | Analyst Rating | The Analyst Target Price has increased from $13.78 to $14.67. | Buy | |
| 2021-02-11 00:51 EST | News | Orchard Therapeutics announces interim data for OTL-203 in mucopolysaccharidosis | N/A | |
About Orchard Therapeutics plc (ORTX):
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
General
- Name Orchard Therapeutics plc
- Symbol ORTX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 224
- Fiscal Year EndDecember
- IPO Date2018-10-31
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.orchard-tx.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 328.42
- Price/Book (Most Recent Quarter) 5.94
- Enterprise Value Revenue 356.95
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.31
- Next Year EPS Estimate -$1.05
- Next Quarter EPS Estimate -$0.36
- Operating Margin -5558%
- Return on Assets -27%
- Return on Equity -64%
- Revenue 2.6 million
- Earnings Per Share -$2.27
- Revenue Per Share $0.03
- Gross Profit 1.74 million
- Quarterly Earnings Growth -100%
View More
Highlights
- Market Capitalization 1 billion
- EBITDA -143886000
- Analyst Target Price $15.11
- Book Value Per Share $1.82
View More
Share Statistics
- Shares Outstanding 123.7 million
- Shares Float 84.94 million
- % Held by Insiders 23%
- % Held by Institutions 67.39%
- Shares Short 5.25 million
- Shares Short Prior Month 4.12 million
- Short Ratio 2.1
- Short % of Shares Outstanding 4%
View More
Technicals
- Beta 1.23
- 52 Week High $12.38
- 52 Week Low $3.76
- 50 Day Moving Average 7.35
- 200 Day Moving Average 5.52
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Orchard Therapeutics plc (ORTX) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Orchard Therapeutics plc (ORTX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-02 | $N/A | -$0.34 | -$0.29 | -18.18% |
| 2020-09-30 | 2020-11-03 | $2 million | -$0.20 | -$0.40 | 49.53% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.42 | -$0.41 | -3.53% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.51 | -$0.50 | -2.41% |
| 2019-12-31 | 2020-02-27 | $595000 | -$0.46 | -$0.43 | -7.85% |
| 2019-09-30 | 2019-11-06 | $1.92 million | -$0.38 | -$0.41 | 8.37% |
| 2019-06-30 | 2019-08-08 | $N/A | -$0.56 | -$0.34 | -63.84% |
| 2019-03-31 | 2019-05-28 | $N/A | -$0.35 | -$0.48 | 27.54% |
| 2018-12-31 | 2019-03-21 | $1.04 million | -$0.35 | -$0.49 | 28.57% |
Orchard Therapeutics plc (ORTX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Orchard Therapeutics plc (ORTX) Chart:
Orchard Therapeutics plc (ORTX) News:
Below you will find a list of latest news for Orchard Therapeutics plc (ORTX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Orchard Therapeutics plc (ORTX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 5 | CALL | 1 | 0 | 294.26 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 11.4 | CALL | 0 | 0 | 181.28 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 123.25 | FALSE | 0 | 0 |
| 2024-05-17 | 10 | 6.4 | CALL | 0 | 4 | 83.88 | FALSE | 0 | 0 |
| 2024-05-17 | 12.5 | 4.1 | CALL | 0 | 10 | 124.22 | FALSE | 0 | 0 |
| 2024-05-17 | 15 | 1.55 | CALL | 0 | 67 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 17.5 | 0.25 | CALL | 0 | 278 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 20 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 22.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.15 | PUT | 0 | 22 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0.1 | PUT | 50 | 50 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.15 | PUT | 5 | 10 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0.05 | PUT | 9 | 37 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 12.5 | 0.05 | PUT | 7 | 113 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 15 | 0.05 | PUT | 0 | 1746 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 17.5 | 1.5 | PUT | 0 | 50 | 32.26 | TRUE | 0 | 0 |
| 2024-05-17 | 20 | 0 | PUT | 0 | 0 | 63.1 | TRUE | 0 | 0 |
| 2024-05-17 | 22.5 | 0 | PUT | 0 | 0 | 65.38 | TRUE | 0 | 0 |
| 2024-05-17 | 25 | 0 | PUT | 0 | 0 | 92.95 | TRUE | 0 | 0 |
| 2024-05-17 | 30 | 0 | PUT | 0 | 0 | 114.44 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | CALL | 0 | 0 | 131.07 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | CALL | 0 | 0 | 86.94 | FALSE | 0 | 0 |
| 2024-08-16 | 10 | 0 | CALL | 0 | 0 | 57.07 | FALSE | 0 | 0 |
| 2024-08-16 | 12.5 | 0 | CALL | 0 | 0 | 34.39 | FALSE | 0 | 0 |
| 2024-08-16 | 15 | 1.5 | CALL | 0 | 59 | 83.63 | FALSE | 0 | 0 |
| 2024-08-16 | 17.5 | 0.05 | CALL | 0 | 48 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 20 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 22.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 10 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 12.5 | 0.05 | PUT | 0 | 42 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 15 | 0.05 | PUT | 0 | 385 | 12.47 | TRUE | 0 | 0 |
| 2024-08-16 | 17.5 | 1.5 | PUT | 0 | 30 | 25.87 | TRUE | 0 | 0 |
| 2024-08-16 | 20 | 0 | PUT | 0 | 0 | 48.54 | TRUE | 0 | 0 |
| 2024-08-16 | 22.5 | 0 | PUT | 0 | 0 | 51.93 | TRUE | 0 | 0 |
| 2024-08-16 | 25 | 0 | PUT | 0 | 0 | 71.73 | TRUE | 0 | 0 |
| 2024-08-16 | 30 | 0 | PUT | 0 | 0 | 88.5 | TRUE | 0 | 0 |
Latest ORTX Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:52 PM EST | 25 | $0.5625 |
| Jun 13, 2022 7:52 PM EST | 200 | $0.561 |
| Jun 13, 2022 7:52 PM EST | 300 | $0.561 |
| Jun 13, 2022 7:52 PM EST | 24 | $0.56 |
| Jun 13, 2022 7:55 PM EST | 100 | $0.5616 |
Orchard Therapeutics plc (ORTX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120037926/0001209191-20-037926-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1748907/000008025520001367/0000080255-20-001367-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000031506620000001/0000315066-20-000001-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000031506620000002/0000315066-20-000002-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1748907/000031506620000757/0000315066-20-000757-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1748907/000110465920021899/0001104659-20-021899-index.htm |
| 2020-04-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1748907/000110465920045219/0001104659-20-045219-index.htm |
| 2020-11-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000110465920122532/0001104659-20-122532-index.htm |
| 2020-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000110465920122542/0001104659-20-122542-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1748907/000119312520027690/0001193125-20-027690-index.htm |
| 2020-02-28 | POSASR | Post-effective Amendment to an automatic shelf registration statement | https://www.sec.gov/Archives/edgar/data/1748907/000119312520053354/0001193125-20-053354-index.htm |
| 2020-03-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000119312520080654/0001193125-20-080654-index.htm |
| 2020-04-14 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1748907/000119312520107148/0001193125-20-107148-index.htm |
| 2020-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1748907/000119312520126076/0001193125-20-126076-index.htm |
| 2020-08-06 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1748907/000119312520211883/0001193125-20-211883-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1748907/000119380520000200/0001193805-20-000200-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000274/0001209191-20-000274-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000277/0001209191-20-000277-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000279/0001209191-20-000279-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000281/0001209191-20-000281-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000283/0001209191-20-000283-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000285/0001209191-20-000285-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000287/0001209191-20-000287-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000290/0001209191-20-000290-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000293/0001209191-20-000293-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120000295/0001209191-20-000295-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120001784/0001209191-20-001784-index.htm |
| 2020-01-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120001811/0001209191-20-001811-index.htm |
| 2020-02-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120006154/0001209191-20-006154-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120006159/0001209191-20-006159-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120016235/0001209191-20-016235-index.htm |
| 2020-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120023123/0001209191-20-023123-index.htm |
| 2020-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120023125/0001209191-20-023125-index.htm |
| 2020-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120036661/0001209191-20-036661-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120037901/0001209191-20-037901-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120037904/0001209191-20-037904-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120037907/0001209191-20-037907-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120037909/0001209191-20-037909-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120037911/0001209191-20-037911-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120037918/0001209191-20-037918-index.htm |
| 2020-06-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000120919120037926/0001209191-20-037926-index.htm |
| 2020-01-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1748907/000138713120000048/0001387131-20-000048-index.htm |
| 2019-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1748907/000156459019041006/0001564590-19-041006-index.htm |
| 2019-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1748907/000156459019041351/0001564590-19-041351-index.htm |
| 2019-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1748907/000156459019043217/0001564590-19-043217-index.htm |
| 2019-11-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1748907/000156459019043762/0001564590-19-043762-index.htm |
| 2019-12-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1748907/000156459019045032/0001564590-19-045032-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020000869/0001564590-20-000869-index.htm |
| 2020-01-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020002373/0001564590-20-002373-index.htm |
| 2020-02-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020002991/0001564590-20-002991-index.htm |
| 2020-02-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020007015/0001564590-20-007015-index.htm |
| 2020-02-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1748907/000156459020007353/0001564590-20-007353-index.htm |
| 2020-03-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020014535/0001564590-20-014535-index.htm |
| 2020-04-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020018675/0001564590-20-018675-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020022353/0001564590-20-022353-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1748907/000156459020022822/0001564590-20-022822-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020025616/0001564590-20-025616-index.htm |
| 2020-06-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020029938/0001564590-20-029938-index.htm |
| 2020-07-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020032077/0001564590-20-032077-index.htm |
| 2020-07-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020032389/0001564590-20-032389-index.htm |
| 2020-07-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020032669/0001564590-20-032669-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020037230/0001564590-20-037230-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1748907/000156459020037239/0001564590-20-037239-index.htm |
| 2020-09-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020042073/0001564590-20-042073-index.htm |
| 2020-09-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020044744/0001564590-20-044744-index.htm |
| 2020-10-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020046580/0001564590-20-046580-index.htm |
| 2020-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020049338/0001564590-20-049338-index.htm |
| 2020-11-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020049768/0001564590-20-049768-index.htm |
| 2020-11-03 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1748907/000156459020049771/0001564590-20-049771-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1748907/000156459020050847/0001564590-20-050847-index.htm |
Orchard Therapeutics plc (ORTX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Orchard Therapeutics plc (ORTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 23%Institutional Ownership: 6739%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-06-11 | FRANK E THOMAS | Officer | Buy | 10,000.00 | 2.44 | 24,400.00 | 25,120.00 | https://www.sec.gov/Archives/edgar/data/1748907/000120919120036661/0001209191-20-036661-index.htm |
| 2020-03-02 | Bobby Gaspar | Officer | Sell | 4,921.00 | 13.00 | 63,973.00 | 348,319.00 | https://www.sec.gov/Archives/edgar/data/1748907/000120919120016235/0001209191-20-016235-index.htm |
| 2020-03-02 | Bobby Gaspar | Officer | Buy | 4,921.00 | 0.00 | 0.49 | 353,240.00 | https://www.sec.gov/Archives/edgar/data/1748907/000120919120016235/0001209191-20-016235-index.htm |
| 2020-01-02 | FMR LLC | 10% Share Holder | Sell | 8,753.00 | 13.41 | 117,377.73 | 6,122,295.00 | https://www.sec.gov/Archives/edgar/data/1748907/000031506620000002/0000315066-20-000002-index.htm |
| 2020-01-02 | FMR LLC | 10% Share Holder | Sell | 5,484.00 | 13.55 | 74,308.20 | 6,131,048.00 | https://www.sec.gov/Archives/edgar/data/1748907/000031506620000002/0000315066-20-000002-index.htm |